Fig. 3

Living imaging and in vivo HIF-α-inhibiting effect of NIR-II-enhanced Pd@Au-PEG NSs. (a) PA imaging of Pd@Au-PEG NSs-injected mice (n = 3) and the quantitative PA signal analysis in tumor at various time points (pre, 2 h, 6 h, 12 and 24 h). (b) CT imaging of Pd@Au-PEG NSs-injected mice (n = 3) at 6 and 24 h post-injection (Red arrows represent the tumor sites). (c) In vivo CT signal in tumor sites post-injection of Pd@Au-PEG NSs. (d) In vivo biodistributions of Pd@Au-PEG NSs by ICP-MS detection (n = 5). (e) Immunofluorescence staining of HIF-α expressions in tumors of Pd@Au-PEG NSs-injected mice at day-1, -3, -5 and  -7 post-injection (Scale bar = 50 μm). (f). The quantitative analysis of HIF-α fluorescence signal intensities